Italian firm Cosmo Pharmaceuticals has announced positive
preliminary results from trials testing out a new formulation of an
antibioticfor traveller's diarrhoea that makes use of the
company's innovative MMX technology.
Cosmo Pharmaceuticals is cementing its place in the inflammatory
bowel disease (IBD) drug market with eight new drugs in various
stages of reformulation using the company's cutting-edge MMX
technology, the company announced recently.
Pharma company Shire has agreed with European regulators on
labelling information for its ulcerative colitis drug Mezavant, a
further step in the firm's ambition to capture more of the $1.6bn
(€1.2bn) mesalazine market through...
Researchers have identified a protein that is thought to defend the
intestinal against microbial invaders offering new insights into
how the intestine fends off pathogens and potentially leading to
new inflammatory bowel disease medications.
The gastrointestinal (GI) market is one of the largest in the
pharma industry and continues to attract a high level of R&D
investment, however, the market has recently entered a crucial
phase, with mounting commercial pressures...
Ferring has opened a new production plant in Switzerland as it
tries to cut costs by centralising its manufacturing network.
In-PharmaTechnologist.com visited the site to see how the drugmaker
is streamlining its supply chain.
In its first venture outside the subcontinent, though certainly not
the last of its kind for India pharma companies, contract
pharmaceuticals manufacturer Kemwell has bought for an undisclosed
sum Pfizer's production plant in...
Nucryst Pharmaceuticals has been granted a new patent that covers
the company's proprietary nanocrystalline silver for use in the
treatment of acne. This latest addition strengthens the company's
patent portfolio, which...
Specialty pharmaceutical firm Shire has filed for approval to
European Regulatory Agencies of SPD476, an ulcerative colitis drug
which uses Cosmo's cutting-edge MMX multi matrix system, promising
to give the company the upper...
Medarex has announced the initiation of a phase I clinical trial of
its human monoclonal antibody for the treatment of ulcerative
colitis after the FDA granted the company an Investigational New
Drug (IND) application.
Serono has licensed rights to a drug that takes a novel approach to
the treatment of ulcerative colitis, a common disease that is
asociated with debilitating symptoms, including cancer, but remains
poorly treated with existing drugs.